Methyl jasmonate leads to necrosis and apoptosis in hepatocellular carcinoma cells via inhibition of glycolysis and represses tumor growth in mice
Metrics: HTML 1274 views | ?
Jingjing Li1, Kan Chen1, Fan Wang1, Weiqi Dai1, Sainan Li1, Jiao Feng1, Liwei Wu1, Tong Liu1, Shizan Xu1,2, Yujing Xia1, Jie Lu1, Yingqun Zhou1, Ling Xu3 and Chuanyong Guo1
1Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
2Department of Gastroenterology, Shanghai Tenth People’s Hospital, School of Clinical Medicine of Nanjing Medical University, Shanghai 200072, China
3Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China
Ling Xu, email: email@example.com
Chuanyong Guo, email: firstname.lastname@example.org
Keywords: Warburg effect, hexokinase 2, hepatoma, methyl jasmonate, glycolysis
Received: December 14, 2016 Accepted: April 11, 2017 Published: April 27, 2017
Methyl jasmonate has recently been found to have anti-cancer activity. Methyl jasmonate detached hexokinase 2 from a voltage dependent anion channel causing a reduction in mitochondrial transmembrane potential that led to the release of cytochrome C and apoptosis inducing factor resulting in intrinsic apoptosis. Blocked adenosine triphosphate synthesis caused by mitochondrial injury hampered oxidative phosphorylation and led to cell necrosis. The results were applied to the in vivo treatment of nude mice with a satisfactory effect. Collectively, our results suggest that methyl jasmonate may be an adjuvant therapy for liver tumors due to its mechanism in cancer cells compared to that in normal cells: The major function is to inhibit glycolysis instead of changing aerobic metabolism.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.